Skip to content
For laboratory research use only. Not for human or veterinary use. Nothing here is medical advice.
123GLP-123 Research Library

Retatrutide CAS Number and Chemical Properties

Retatrutide CAS number and chemical properties: molecular formula, mass, structure, receptor pharmacology, and identity checks for laboratory records.

6 min read Published Updated Retatrutide
Retatrutide CAS Number and Chemical Properties
Quick answer

Retatrutide's commonly cited CAS Registry Number is 2381089-83-2, and its generally described molecular formula is C221H342N46O68 with an average molecular weight of about 4,731.3 g/mol. A CAS number alone does not confirm purity, composition, or quality, so it should be paired with batch-specific analytical data.

Retatrutide CAS number and chemical properties are foundational identifiers for laboratory records, analytical method development, and comparison of batch documentation. Retatrutide is a synthetic, lipidated peptide investigated in published literature as an agonist with activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Its large molecular size, modified peptide architecture, and amphiphilic lipid substituent make identity confirmation more complex than a simple small-molecule catalog entry.

Retatrutide CAS Number and Chemical Properties

The commonly cited CAS Registry Number for retatrutide is 2381089-83-2. A CAS number is a numerical identifier assigned to a specific substance record by the Chemical Abstracts Service. It supports unambiguous database searching and helps distinguish retatrutide from related incretin peptides, sequence variants, intermediates, salts, and formulation-specific materials.

A CAS number should not be treated as a standalone confirmation of composition or quality. It identifies the chemical entity referenced in a registry, but it does not establish a particular material’s purity, peptide content, counterion profile, residual solvent level, or storage history. For that reason, laboratory documentation typically evaluates the CAS identifier alongside a batch-specific certificate of analysis, molecular-mass data, chromatographic purity data, and, where applicable, sequence or structural confirmation.

Retatrutide is generally described with the molecular formula C221H342N46O68 and an average molecular weight of approximately 4,731.3 g/mol. Small reporting differences can appear when a source reports a salt form, hydration state, a monoisotopic mass, or a molecular mass rounded to a different number of decimal places. Analytical records should therefore specify which mass convention is being used.

A Modified Peptide Rather Than a Simple Receptor Ligand

Retatrutide is a 39-amino-acid synthetic peptide engineered to interact with three metabolically relevant class B G protein-coupled receptors. Its design reflects a broader trend in peptide chemistry: receptor pharmacology is adjusted not only through amino-acid substitutions but also through covalent modification intended to alter circulation time and distribution behavior in experimental models.

The compound includes a fatty-acid-derived moiety attached through a linker system. This lipidation is chemically significant. A peptide alone is highly polar and may be rapidly cleared or enzymatically processed under experimental conditions. Adding a lipidated side chain can increase association with serum albumin, which is one mechanism used in peptide design to extend apparent exposure. The modification also contributes to retatrutide’s amphiphilic character, meaning the molecule contains both water-compatible peptide regions and a comparatively hydrophobic lipid region.

That mixed chemical character affects analytical behavior. In reversed-phase liquid chromatography, retention can be influenced by the peptide sequence, the fatty-acid substituent, mobile-phase composition, column chemistry, temperature, and the presence of closely related peptide species. A method suitable for a smaller, non-lipidated peptide may therefore require adjustment before it can provide adequate separation of retatrutide and related impurities.

Molecular mass and mass-spectrometry interpretation

With an average molecular mass near 4.7 kDa, retatrutide sits within a range where electrospray ionization mass spectrometry commonly produces a distribution of multiply charged ions rather than one dominant singly charged ion. Deconvolution is used to infer the neutral molecular mass from that charge-state envelope.

For peptide identity work, agreement between the observed deconvoluted mass and the expected theoretical mass provides valuable evidence, but it is not complete structural proof on its own. Oxidation, truncation, deletion sequences, deamidation, incomplete side-chain modification, and adduct formation can generate related species with subtle or potentially overlapping analytical signatures. Orthogonal methods, particularly chromatographic purity assessment and targeted peptide characterization, help resolve those possibilities.

Formula composition and what it implies

The formula C221H342N46O68 reflects the high heteroatom content expected of a peptide. Nitrogen originates principally from backbone amide groups and nitrogen-containing amino-acid side chains. Oxygen is contributed by peptide carbonyls, hydroxyl-containing residues, carboxyl groups, and the lipid-linker architecture.

This composition has practical consequences for the molecule’s physicochemical profile. Retatrutide is not expected to behave as a volatile analyte under conventional gas chromatography conditions. It is better suited to liquid-phase methods and mass-spectrometric characterization. Its many ionizable groups also mean that observed charge, solubility, and chromatographic retention vary with pH, buffer selection, ionic strength, and solvent composition.

Receptor Activity in the Literature

Retatrutide is commonly classified as a triple agonist because it exhibits activity at GIP, GLP-1, and glucagon receptors. These receptors are expressed across several tissues and are studied for their roles in glucose handling, energy expenditure, lipid metabolism regulation, and satiety signaling pathway interaction. The triple-agonist concept differs from a single-pathway peptide model because pharmacological behavior is shaped by the relative activity at each receptor, not merely whether binding occurs.

Published preclinical and clinical literature has examined this pharmacology in metabolic settings. From a molecular-research perspective, the central point is that receptor activation is context-dependent. Results can vary with receptor expression level, assay format, species-specific receptor sequence, incubation duration, and the endpoint selected. Cyclic AMP assays, receptor-binding studies, beta-arrestin measurements, and cell-based functional assays may each describe different aspects of agonist behavior.

The peptide’s glucagon receptor component deserves particular analytical attention because glucagon-pathway signaling can influence energy metabolism differently from GLP-1 or GIP signaling. Consequently, interpreting retatrutide data requires more than describing it as a member of the incretin peptide class. Its chemical design and three-receptor activity profile should be considered together.

Identity, Purity, and Batch Comparability

For a compound of this size and structural complexity, a molecular formula and CAS number are starting points, not a complete verification package. A defensible laboratory record generally connects the declared identity to analytical evidence. High-performance liquid chromatography can characterize the principal peak and related species, while mass spectrometry can assess molecular-mass agreement. Additional methods may be appropriate where sequence confirmation, counterion determination, water content, or residual solvent evaluation is relevant to the study design.

Purity percentages also require context. A chromatographic purity result describes the area relationship under a stated method and detection condition. It does not automatically equal peptide-content percentage by mass, nor does it quantify every potential non-chromophoric impurity with equal sensitivity. Comparing certificates from different lots or suppliers is therefore most meaningful when the analytical method, column conditions, detection wavelength, reference standard approach, and reported acceptance criteria are available.

Storage and handling records influence comparability as well. Peptides can be vulnerable to moisture exposure, repeated temperature cycling, oxidation at susceptible residues, aggregation, and adsorption to certain surfaces. The lipidated structure may further affect solution behavior. In analytical work, observed changes should be interpreted against controlled handling conditions rather than assigned to intrinsic instability without supporting evidence.

Retatrutide is sometimes discussed alongside semaglutide and tirzepatide because all three are modified peptide compounds investigated in metabolic research. Their shared peptide classification, however, should not be mistaken for interchangeability. They differ in amino-acid sequence, receptor activity profile, molecular mass, lipidation design, and analytical fingerprint.

Semaglutide is principally associated with GLP-1 receptor agonism, while tirzepatide has dual GIP and GLP-1 receptor activity. Retatrutide adds glucagon receptor agonism to GIP and GLP-1 activity. These distinctions affect both experimental interpretation and material identification. A record that lists only a broad class label, such as GLP-related peptide, is less informative than one that documents the exact chemical name, CAS number, formula, mass specification, lot identifier, and supporting analytical results.

For researchers and laboratory operators, the useful question is not simply whether an identifier appears on a label. The more meaningful question is whether the identifier connects to a traceable set of data that can withstand comparison across methods, batches, and study timelines. Retatrutide’s CAS number and chemical properties provide that starting framework, while carefully matched analytical documentation gives the framework scientific value.

> “Disclaimer: The chemical entities semaglutide, tirzepatide, and retatrutide referenced in this literature review are specialized research peptides intended solely for laboratory evaluation and in v

Originally published on glp-123.com. This library mirrors the guide for easier reading. Products mentioned are for laboratory research only.

View original